Elan boss: Climate improved for Alzheimer's drugs

The stakes are high for the experimental Alzheimer's drug bapineuzumab, which analysts give a low chance of proving effective against the memory-stealing disease. With a 25% stake in the drug, which Pfizer ($PFE) and Johnson & Johnson ($JNJ) are developing, Elan ($ELN) has a lot riding on the success of bapineuzumab. And Elan Chairman Robert Ingram gave shareholders a bit of a pep talk ahead of pivotal trial data due to be released in the second half of this year. "We don't know the data yet but the environment today versus two years ago has changed for the positive," Ingram said, as quoted by the Irish Independent. The chairman noted that the White House has emphasized the need for new Alzheimer's drugs and regulators could stamp an approval on a drug that could show even modest benefits for patients. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.